



Docket No.: A0871.70001US00  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Rong-Hwa Lin et al.  
Serial No.: 10/662,906  
Confirmation No.: 1268  
Filed: September 15, 2003  
For: MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1  
Examiner: P. Gambel  
Art Unit: 1644

**Certificate of Mailing Under 37 CFR 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: Sept. 11, 2007

  
Alan W. Steele, M.D., Ph.D., Registration No. 45,128

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement set forth in the Office Action mailed June 11, 2007, Applicant hereby provisionally elects Group II, claim 39, for continued examination. Applicant further elects species (A) homomeric and (D) an anti-PSGL-1 antibody, in accordance with an election of species requirement also set out by the examiner in the Restriction Requirement.

**Remarks**

The examiner has required restriction between Group I, claims 1-38, drawn to methods of reducing T cell-mediated immune responses with multimeric compounds which bind PSGL-1 proteins, and Group II, claim 39, drawn to a kit comprising PSGL-1-binding multimeric compounds. In response, Applicant has elected Group II, claim 39, for examination on the merits.